Experiments have suggested that antibodies blocking IL-1β can prevent cardiovascular events and reduce the incidence and mortality of lung cancer, emphasizing the importance of IL-1 and related family members (such as IL-33 and IL-18) in shaping the innate immunity and inflammation responses (61, 62). Here, IL33 is linked to lung carcinoma.